RxDoctor Payments Data

Jennifer Schoenfeld, APRN

Adult Health · Rockwall, TXNPI 1265026801

Payments from drug & device makers

$3,916in general payments, 2019–2025

Across 203 payments — averaging $19.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$532
  • AbbVie$451
  • Novo Nordisk$347
  • Pfizer$236
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$224
  • Teva Pharmaceuticals USA, Inc.$216
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$3,916100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,916 in reported general payments places this provider in the 85th percentile of 933 adult health providers in Texas.

See all adult health providers in Texas

Medicare billing

Part B allowed, 2024
$122,156
Medicare patients
381
Services billed
1,474

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$63,638
RybelsusSemaglutide41$60,973
EliquisApixaban58$51,354
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$31,992
TrulicityDulaglutide18$30,027
JardianceEmpagliflozin20$24,073
MounjaroTirzepatide19$22,776
JanuviaSitagliptin Phosphate11$18,103
MyrbetriqMirabegron19$15,006
LinzessLinaclotide21$14,266
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$12,588
Tresiba Flextouch U-100Insulin Degludec13$8,422
XareltoRivaroxaban12$6,424
Combivent RespimatIpratropium/Albuterol Sulfate12$5,775
Albuterol Sulfate HfaAlbuterol Sulfate146$3,730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$347$124,61193 claims
Lilly USA, LLCTrulicity, Mounjaro$184$52,80437 claims
PfizerEliquis$236$51,35458 claims
GSKTrelegy Ellipta$68$31,99239 claims
Boehringer IngelheimJardiance, Combivent Respimat$18$29,84832 claims
Astellas Pharma US IncMyrbetriq$58$15,00619 claims
AbbVieLinzess$451$14,26621 claims
AstraZenecaBreztri Aerosphere$198$12,58819 claims
Johnson & JohnsonXarelto$130$6,42412 claims
Sanofi-aventis U.S. LLCLantus$56$3,19335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 933 adult health providers in Texas.

Other adult health in Rockwall

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →